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In the 3 years since the publication of the much anticipated results of the National Lung Cancer Screening Trial (NLST), there has been increased acceptance that screening of 
high-risk populations is indeed effective in the reduction of lung cancer and all-cause 
mortality. More and more organizations adopt lung cancer screening guidelines,1,2 mostly 
aligned with the NLST protocol. As such, the US Preventive Services Task Force recently 
upgraded low-dose computed tomography (CT) screening to a Grade B recommendation.3
However, gaps in knowledge still exist that are primarily related to the practical 
aspects of implementing screening on a larger scale. Concerns focus around the transla-
tion of the NLST results to less controlled environments and mainly around the harms of 
screening. It was these concerns that resulted in a low-confidence vote from the Medicare 
Evidence Development & Coverage Advisory Committee just last month.4
This issue of the Journal of Thoracic Oncology includes two articles that, whereas 
different, both address harms from lung cancer screening.5,6 In general, there are two 
major categories of harms from screening—physical and psychological.7 The article from 
Veronesi et al.6 focuses on the physical harms, whereas Slatore et al.5 addresses the psycho-
logical harms related to lung cancer screening.
The major cause of physical harm in the context of lung cancer screening stems 
from the invasive evaluation of nodules seen on a screening CT. Veronesi et al.6 analyze 
the performance of the diagnostic protocol use in the continuous observation of smoking 
subjects study (COSMOS), a single-center observational study with a 79% 5-year compli-
ance rate. COSMOS differs from most other observational screening studies by a having a 
slightly lower risk screening cohort and a higher nodule threshold for recall (5 mm versus 
4 mm). Their results related to protocol performance, recall rate and 5-year compliance rate 
provide an indication of how a screening program can perform in a setting different than 
what was used by NLST.
One major protocol difference highlighted in Veronesi et al.6 is the definition of false 
positives (FP). The most common FP definition is any nodule (above a given size) seen on 
a screening CT that is ultimately regarded as benign. Veronesi et al.6 define FP as nodules 
“treated by surgical biopsy” but determined to be benign; nodules deemed benign by non-
invasive follow-up are labeled indeterminate. Based on this definition of FP, the protocol 
had 90% sensitivity and an 84.5% positive predictive value, an 8% false negative rate, and 
6% FP rate. For comparison, the NLST reports a FP rate of 27% at baseline.8 Although this 
change in definition “greatly increases screening specificity,” it does not actually decrease 
the harms to the screened individual; the morbidity from invasive nonsurgical procedures 
and the psychological harms from the presence of a nodule seen on a baseline screening 
CT do still occur. Algorithms for follow-up of screen-detected lung nodules are needed, in 
particular because the NLST does not recommend anything beyond standard of care, which 
may be different at each institution. Caution, however, needs to be taken by assuming that a 
change in definition may alter the risk and harms for the participants.
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In the second lung cancer screening article in this issue, 
Slatore et al.5 focus on the psychological harms of screening. 
The authors present a systematic review of patient-centered 
outcomes in lung cancer screening study participants, where 
the outcomes of interest were quality of life, distress, and 
anxiety. After an extensive literature search, they reviewed six 
studies that described psychosocial consequences of low-dose 
CT screening. That they were only able to identify a small 
number of studies to be included in their systematic review 
is a reflection of the underrepresentation of research into the 
psychological aims of lung cancer screening. To be fair, this 
dearth is present in other cancer screening contexts as well.9 In 
lung cancer screening, however, the rate of FPs is high, which 
makes it especially important to address the psychological 
harm and understand the various effects that the screening 
process overall may have on the participant.7 Quality of Life 
and anxiety metrics should be part of lung cancer screening 
studies, as they are in the Pan Canadian Early Detection of 
Lung Cancer Study10 which will yield important information 
on the acceptance of lung cancer screening.
Slatore et al.5 concluded that in the short-term, screen-
ing was associated with negative effects but did not impact 
distress, worry or health-related quality of life. FP results were 
also associated with short-term increases in distress, although 
there was an eventual return to levels similar to those observed 
in participants with negative results. This short-lived distress 
offers a perfect opportunity for intervention. Because distress 
is related to not just a positive result but the actual wait for a 
result, ideal screening scenarios would include a 1-day visit 
that covers everything from risk assessment, CT scanning, 
real time reading and reporting, smoking counseling, trans-
mission of results, and a consult with specialists in the pres-
ence of a positive finding. Although these one-stop screening 
programs do exist, they are not realizable or cost-effective in 
most hospital environments. The second best approach may 
be what Slatore et al.5 suggest, which is improved informa-
tion and communication. Clinicians and screening staff must 
make sure that the screening participant is not left wondering 
what will happen next and when it will happen. For example, 
a timeline for the results can be provided at the time of the 
CT, and in the presence of a positive finding they also receive 
the time and date for their follow-up appointment. Logistics 
at most institutions should be available to offer this patient-
centered approach.
In summary, addressing the major categories of harms 
from lung cancer screening is a timely and pressing issue, 
as evidenced by the reasons behind the Medicare Evidence 
Development & Coverage Advisory Committee low-confi-
dence vote. The results from studies such as Veronesi et al.6 
and Slatore et al.5 help fill the knowledge gaps so that the deci-
sion makers can more accurately evaluate how to effectively 
implement screening. We need strategies to identify, commu-
nicate, and mitigate screening harms and target populations, 
which will result in an informed public and caregiver commu-
nity that is accepting of the screening experience.
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